Infigratinib phosphate - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for infigratinib phosphate and what is the scope of patent protection?
Infigratinib phosphate
is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Infigratinib phosphate has one hundred and thirty-three patent family members in forty countries.
One supplier is listed for this compound.
Summary for infigratinib phosphate
International Patents: | 133 |
US Patents: | 4 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 28 |
Clinical Trials: | 1 |
Patent Applications: | 26 |
DailyMed Link: | infigratinib phosphate at DailyMed |
Recent Clinical Trials for infigratinib phosphate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Emory University | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for infigratinib phosphate
International Patents for infigratinib phosphate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E045156 | See Plans and Pricing | |
China | 103121972 | Pyrimidine urea derivatives as kinase inhibitors | See Plans and Pricing |
Croatia | P20160126 | See Plans and Pricing | |
Taiwan | 201144297 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof | See Plans and Pricing |
Japan | 6804585 | See Plans and Pricing | |
South Africa | 201203612 | CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4[(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |